Tirzepatide vs Retatrutide: Head-to-Head Comparison
Tirzepatide is an FDA-approved dual GIP/GLP-1 agonist achieving up to 22.5% weight loss. Retatrutide is an investigational triple agonist (GIP/GLP-1/glucagon) showing up to 24.2% weight loss in Phase 2 — the highest ever recorded. Tirzepatide is available now; retatrutide is still in Phase 3 trials.
Approved options in this comparison
Tirzepatide is currently modeled on this site as an approved treatment path for: Type 2 diabetes mellitus; chronic weight management in adults with obesity or overweight with comorbidities. Brand names in the current dataset: Mounjaro, Zepbound.
Want to discuss Tirzepatide with a provider?
Tirzepatide is currently modeled on this site as an approved treatment path. Use the provider matcher to narrow fit by state, insurance, budget, and urgency.
Join provider rolloutTirzepatide Next Steps
FR selected - using US-first conversion assetsUse the reviewed cost hub before you commit to a provider path or a self-pay workflow.
Open cost guide ->Validate reminder, refill, and symptom-tracking demand before the full PWA launches.
Open tracker landing ->Side-by-Side Comparison
| Dimension | Tirzepatide | Retatrutide |
|---|---|---|
| Evidence Level | Level A — Phase 3 RCTs (SURMOUNT, SURPASS) | Level B — Phase 2 RCT; Phase 3 ongoing |
| FDA Status | Approved for T2D (Mounjaro) and obesity (Zepbound) | Not approved; Phase 3 trials (TRIUMPH program) |
| Weight Loss Efficacy | Up to 22.5% (SURMOUNT-1 at 72 weeks) | Up to 24.2% (Phase 2 at 48 weeks) |
| Mechanism | Dual agonist: GIP + GLP-1 receptors | Triple agonist: GIP + GLP-1 + glucagon receptors |
| Liver Fat Reduction | Moderate liver fat reduction observed | Significant liver fat reduction via glucagon activation |
| Availability | Available by prescription now | Not yet available; expected 2026-2027 |
Peptide Overviews
Tirzepatide
AFDA ApprovedTirzepatide is the first dual GIP and GLP-1 receptor agonist, approved by the FDA for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound). Achieves unprecedented weight loss in clinical trials.
Retatrutide
BHuman StudiesRetatrutide is an investigational triple-hormone receptor agonist developed by Eli Lilly. It simultaneously targets GIP, GLP-1, and glucagon receptors, achieving the highest weight loss ever reported in an obesity clinical trial — up to 24.2% at 48 weeks.
GLP-1 Support Essentials
Products that can support side-effect management, hydration, and protein intake.
LMNT Electrolyte Packets
Sodium-focused electrolytes to prevent dehydration and fatigue common in early GLP-1 therapy.
High-Protein Shakes (30g)
Convenient protein shakes to maintain muscle mass on reduced GLP-1 caloric intake.
Metamucil Fiber Supplement
Soluble fiber powder to manage constipation and GI side effects during GLP-1 treatment.
Vitamin B12 (Methylcobalamin 1000mcg)
GLP-1 agonists can reduce B12 absorption over time — methylcobalamin is the most bioavailable form.
Ginger Chews for Nausea
Natural nausea relief for the dose-escalation adjustment period, particularly weeks 1–4.
Unflavored Whey Protein Isolate
Preserve lean mass without excess carbs or calories when appetite is suppressed.
Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.
Supplies for Both
Common research handling and preparation supplies for injectable peptide workflows.
Alcohol Prep Pads (200 ct)
Sterile 70% isopropyl pads for injection site preparation — essential for subcutaneous protocols.
1mL Insulin Syringes (28G)
Thin-gauge 28G syringes for subcutaneous peptide administration with minimal discomfort.
Sharps Disposal Container (1 Qt)
Biohazard-safe sharps container for responsible disposal of used syringes.
Digital Milligram Scale (0.001g)
High-precision scale for accurate measurement of peptide powder before reconstitution.
Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.
Recommended Reading
Books covering peptide science, longevity research, and biohacking frameworks.
The Peptide Protocols
Comprehensive reference for peptide mechanisms, dosing research, and clinical applications.
Boundless by Ben Greenfield
Covers peptides, nootropics, hormones, and longevity strategies in an optimization framework.
Lifespan by David Sinclair
Evidence-based deep-dive into aging science, directly relevant to longevity peptide research.
The Longevity Paradox
Gut-centric aging research with diet and supplementation protocols for extending healthspan.
Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.
Tirzepatide vs Retatrutide: FAQ
Join the France comparison waitlist
We will notify you when France-specific legal, pricing, provider, and tracker flows are available for comparison pages.
No spam. Unsubscribe anytime.
Medical Disclaimer
This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.
No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.